What's breaking now, across thousands of outlets.
Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
(MedPage Today) -- Note that some links may require registration or subscription. The fastest-growing Ebola outbreak on record in eastern Congo is rapidly spreading beyond its epicenter, the Africa…
That morning brew may be doing you more harm than good. A study of almost 1 million tea and coffee drinkers has linked very hot drinks to a threefold greater risk of developing one type of esophageal…
Retired detective Phil Alvarez, whose brother Luis died of cancer linked to the toxins at Ground Zero, talks about marking 25 years since the Sept.
Platinum chemotherapy's long-term effects, surprising heart failure drug failures, and more biotech news from The Readout
At NLS Days 2026, life science companies and a record number of investors attended to showcase data, partner, and raise funding. The post NLS Days 2026: what’s dealmaking like in the Nordics?
The Society for Healthcare Epidemiology of America (SHEA) has published a new resource describing how diagnostic stewardship can improve patient outcomes, strengthen hospital quality metrics and…
